Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma |
| |
Authors: | Yi-Gang Wang Pan-Pan Huang Rong Zhang Bu-Yun Ma Xiu-Mei Zhou Yan-Fang Sun |
| |
Affiliation: | Yi-Gang Wang, Pan-Pan Huang, Rong Zhang, Bu-Yun Ma, Xiu-Mei Zhou, Yan-Fang Sun, Xinyuan Institute of Medicine and Biotechnology, School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China |
| |
Abstract: | Human hepatocellular carcinoma (HCC) heavily endangers human heath worldwide. HCC is one of most frequent cancers in China because patients with liver disease, such as chronic hepatitis, have the highest cancer susceptibility. Traditional therapeutic approaches have limited efficacy in advanced liver cancer, and novel strategies are urgently needed to improve the limited treatment options for HCC. This review summarizes the basic knowledge, current advances, and future challenges and prospects of adeno-associated virus (AAV) and adenoviruses as vectors for gene therapy of HCC. This paper also reviews the clinical trials of gene therapy using adenovirus vectors, immunotherapy, toxicity and immunological barriers for AAV and adenoviruses, and proposes several alternative strategies to overcome the therapeutic barriers to using AAV and adenoviruses as vectors. |
| |
Keywords: | Hepatocellular carcinoma Adeno-associated virus Adenovirus Virus vectors |
|
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|